This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Study acronym: MSTH-CAR002
StatusEnrolling by Invitation
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrolling by invitation only Show 6 more changesShow less
    • Start date changed from estimate of Jan 1, 2026 to Oct 10, 2026
    • Study completion pushed from Dec 2031 to Dec 2032
    • Interventions: CD19/22 CAR-T cells (Biological) to CD19/22 CAR-T cells (Biological)
    • Eligibility criteria expanded, about 23 words
    • Study site revised
    • Study description expanded, about 1 word
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Trial Details
NCT Number NCT07162571
Lead Sponsor Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Conditions
(from sponsor)		 Acute Lymphobkastic Leukemia, B Cell Lymphoma
Related terms Lymphoma, B-Cell
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov